<?xml version="1.0" encoding="UTF-8"?>
<results title="disease">
 <result pre=", This article is being made freely available through PubMed" exact="Central" post="as part of the COVID-19 public health emergency response."/>
 <result pre="health emergency.file:DDR-9999-na.pdf Abstract Abstract Coronavirus diseaseâ€�19 (COVIDâ€�19), caused by severe" exact="acute" post="respiratory syndrome coronavirus 2 (SARSâ€�CoVâ€�2), is one of the"/>
 <result pre="emergency.file:DDR-9999-na.pdf Abstract Abstract Coronavirus diseaseâ€�19 (COVIDâ€�19), caused by severe acute" exact="respiratory" post="syndrome coronavirus 2 (SARSâ€�CoVâ€�2), is one of the most"/>
 <result pre="Abstract Abstract Coronavirus diseaseâ€�19 (COVIDâ€�19), caused by severe acute respiratory" exact="syndrome" post="coronavirus 2 (SARSâ€�CoVâ€�2), is one of the most contagious"/>
 <result pre="China has already emerged as a global pandemic with a" exact="total" post="of 10,421,869 cases, including 508,422 deaths, as of June"/>
 <result pre="the similar previous outbreaks such as SARS and Middle East" exact="Respiratory" post="Syndrome (MERS) share common signs and symptoms, such as"/>
 <result pre="similar previous outbreaks such as SARS and Middle East Respiratory" exact="Syndrome" post="(MERS) share common signs and symptoms, such as sore"/>
 <result pre="signs and symptoms, such as sore throat, persistent high fever," exact="pneumonia" post="with common pathologies, such as immune dysfunction, and multiâ€�organ"/>
 <result pre="(RdRp) are among the nonstructural proteins that are critical for" exact="viral" post="replication (Forster et al., 2020; Siu et al., 2008)."/>
 <result pre="Siu et al., 2008). With their significant roles in the" exact="viral" post="life cycle, these proteins present promising pharmacological targets for"/>
 <result pre="are usually employed to carry out the TDD for the" exact="complete" post="understanding of any drug candidate and also ensuring the"/>
 <result pre="(Harrison, 2020). Some of the existing antiviral drugs from other" exact="viral" post="diseases, including Remdesivir, are being considered as repurposing medicine"/>
 <result pre="whereas the S, E, and M proteins together shape the" exact="viral" post="envelope, and the glycoprotein spikes render coronaviruses to form"/>
 <result pre="prevent and treat SARSâ€�CoV and SARSâ€�like coronavirus (SLâ€�CoV), including SARSâ€�CoVâ€�2" exact="infections" post="in the future. Crucial steps of SARSâ€�CoV life cycle"/>
 <result pre="2 (ACE2). S protein is then proteolytically cleaved by a" exact="type II" post="transmembrane protease (TMPRSS2) resulting into two subunits called S1"/>
 <result pre="of the S protein by proteases is essential for the" exact="viral" post="entry to the host cells in a pHâ€�dependent manner"/>
 <result pre="cell. Then the polyprotein is split into effector proteins by" exact="viral" post="proteinases (3CLpro and PLpro), resulting in a number of"/>
 <result pre="Perlman, 2015; Sola et al., 2015; Stertz et al., 2007)." exact="Viral" post="nucleocapsids are assembled with genomic RNA and N protein"/>
 <result pre="al., 2009). S, Spike protein; E, envelope protein; singleâ€�stranded positiveâ€�sense" exact="viral" post="RNA, and M, membrane protein are depicted. (b) A"/>
 <result pre="(5) structural protein synthesis and maturation, and (6) Assembly of" exact="viral" post="particles and mature viral particle. 3CLpro, chymotrypsinâ€�like protease; ACE2,"/>
 <result pre="and maturation, and (6) Assembly of viral particles and mature" exact="viral" post="particle. 3CLpro, chymotrypsinâ€�like protease; ACE2, Angiotensinâ€�converting enzyme 2; E,"/>
 <result pre="hold promise for the development of potential therapy against SARSâ€�CoVâ€�2" exact="infections" post="(Figure 2). FIGURE 2 A schematic diagram indicating the"/>
 <result pre="schematic diagram indicating the potential drug targets and drugs on" exact="viral" post="replication processes. (1) ACE2 and spike complex inhibitors: Azithromycin"/>
 <result pre="Targeting endosomes: chloroquine and its derivatives increase pH and inhibit" exact="viral" post="RNA release from endosomes; (4) Targeting proteases: ASC09F, Oseltamivir,"/>
 <result pre="ASC09F, Oseltamivir, Ritonavir, Oseltamivir, Oseltamivir, Lopinavir inhibit proteases thereby inhibit" exact="viral" post="replication; (5) Targeting RdRp: Favipiravir, Remdesivir, and Ribavirin block"/>
 <result pre="ribosomal frameshift, are hydrolyzed by an extensive proteolytic action of" exact="viral" post="proteases (Fehr &amp;amp; Perlman, 2015; Graham, Sparks, Eckerle, Sims,"/>
 <result pre="Manickam, Namasivayam, Hayashi, &amp;amp; Jung, 2016). One of the crucial" exact="viral" post="proteases is the Mpro, also known as 3Câ€�like proteinase"/>
 <result pre="Papain like protease Proteolytic enzymes play an essential role in" exact="viral" post="replication, and hence could be the target of choice"/>
 <result pre="target of choice for the development of effective therapy against" exact="viral" post="infections. PLpro, also termed as NSP 3, had been"/>
 <result pre="NSP1, NSP2, and NSP3, a process that is crucial for" exact="viral" post="replication. The cleavage specificity of PLpro corresponds to the"/>
 <result pre="therapeutic strategy that would be advantageous in not only preventing" exact="viral" post="replication but also ensuring the normal regulation of signal"/>
 <result pre="druggable target for the development of potent therapy against SARSâ€�CoVâ€�2" exact="infection" post="(Kandeel, Ibrahim, Fayez, &amp;amp; Alâ€�Nazawi, 2020; Lung et al.,"/>
 <result pre="a prodrug and adenosine analog, can be incorporated into nascent" exact="viral" post="RNA, and subsequently inhibit the RdRp (Siegel et al.,"/>
 <result pre="2017). Furthermore, Remdesivir showed high considerable efficacy in controlling SARSâ€�CoVâ€�2" exact="infection" post="in a recent in vitro study (Wang et al.,"/>
 <result pre="ribonucleoside analog, also inhibits SARSâ€�CoVâ€�2 replication as evidenced by reducing" exact="viral" post="genomic RNA (Sheahan et al., 2020). Helicase SARSâ€�CoV helicase"/>
 <result pre="al., 2003) and can also be evaluated against SARSâ€�CoVâ€�2. 3.1.2" exact="Structural" post="protein target Spike glycoprotein The spike protein (S), giving"/>
 <result pre="possesses a large ectodomain, a singleâ€�pass transmembrane anchor, and a" exact="short" post="intracellular tail (Li, 2016). The ectodomain consists of a"/>
 <result pre="changes in the S2 subunit assist the fusion between the" exact="viral" post="envelope protein and the host cell membrane (Du et"/>
 <result pre="cellular environment cause the cleavage of S proteins, which ensures" exact="viral" post="fusion. SARSâ€�CoVâ€�2 possesses a furin cleavage site between S1"/>
 <result pre="that permits efficient cleavage by proteases, including furin that determines" exact="viral" post="infectivity and host range (Andersen et al., 2020; Coutard"/>
 <result pre="vaccine development. Envelope protein E protein of coronavirus is a" exact="short" post="polypeptide integral membrane protein that has been involved with"/>
 <result pre="absence or inactivation of E protein could impact either virion" exact="morphology" post="or tropism (Khattari et al., 2006; Pervushin et al.,"/>
 <result pre="McKinlay, Gage, &amp;amp; Ewart, 2004). SARSâ€�CoVs lacking E protein show" exact="lower" post="viral titer, immature, and inefficient progenies (Kuo, Hurst, &amp;amp;"/>
 <result pre="Gage, &amp;amp; Ewart, 2004). SARSâ€�CoVs lacking E protein show lower" exact="viral" post="titer, immature, and inefficient progenies (Kuo, Hurst, &amp;amp; Masters,"/>
 <result pre="thereby recommending E protein a suitable drug target to prevent" exact="viral" post="replication and infection. 3.2 Host cell target 3.2.1Angiotensinâ€�converting enzyme"/>
 <result pre="3.2 Host cell target 3.2.1Angiotensinâ€�converting enzyme 2 ACE2 is a" exact="type I" post="membrane protein, which is expressed in the heart, lungs,"/>
 <result pre="have facilitated a more favorable personâ€�toâ€�person transmission of the SARSâ€�CoVâ€�2" exact="infection" post="than the SARSâ€�CoV (Hoffmann et al., 2020). ACE2 can"/>
 <result pre="thus act as a unique adhesion protein molecule for SARSâ€�CoVâ€�2" exact="infection" post="and be a promising drug target for the prevention"/>
 <result pre="found that hrsACE2 can preclude the early entrance of SARSâ€�CoVâ€�2" exact="infections" post="in host cells perhaps by binding with RBD of"/>
 <result pre="serine protease 2 Although the ACE2 is available in the" exact="vascular" post="endothelial cells of all organs, the lungs are more"/>
 <result pre="of all organs, the lungs are more susceptible to SARSâ€�CoV" exact="infection" post="(Hamming et al., 2004). This phenomenon strengthens the possibility"/>
 <result pre="pathogenesis of SARSâ€�CoVâ€�2. One such factor which accounts for the" exact="viral" post="entry into host cells is TMPRSS2, a wellâ€�known human"/>
 <result pre="found to cleave SARSâ€�CoV S protein and to moderately accelerate" exact="viral" post="infections (Kam et al., 2009). TMPRSS2 probably facilitates viral"/>
 <result pre="to cleave SARSâ€�CoV S protein and to moderately accelerate viral" exact="infections" post="(Kam et al., 2009). TMPRSS2 probably facilitates viral pathogenesis"/>
 <result pre="accelerate viral infections (Kam et al., 2009). TMPRSS2 probably facilitates" exact="viral" post="pathogenesis and transmission in two ways: First, TMPRSS2 might"/>
 <result pre="protein for virusâ€&quot;cell and cellâ€&quot;cell fusion. Second, TMPRSS2 might protect" exact="viral" post="recognition by different neutralizing antibodies of the host (Glowacka"/>
 <result pre="TMPRSS2â€�expressing in VeroE6 cell line is highly susceptible to SARSâ€�CoVâ€�2" exact="infection" post="displaying the critical role of TMPRSS2 in the pathogenesis"/>
 <result pre="the critical role of TMPRSS2 in the pathogenesis of this" exact="viral" post="disease. Previously, Bromhexine hydrochloride, an FDA approved component in"/>
 <result pre="showed specific inhibition on TMPRSS2 with no adverse effect in" exact="prostate cancer" post="patients and reduction of the progression of metastasis (Lucas"/>
 <result pre="specific inhibition on TMPRSS2 with no adverse effect in prostate" exact="cancer" post="patients and reduction of the progression of metastasis (Lucas"/>
 <result pre="in prostate cancer patients and reduction of the progression of" exact="metastasis" post="(Lucas et al., 2014). Bromhexine hydrochloride might be repurposed"/>
 <result pre="might be repurposed as a TMPRSS2 inhibitor for preventing SARSâ€�CoVâ€�2" exact="infection" post="as well (Hoffmann et al., 2020). 3.2.3 Targets on"/>
 <result pre="causes imbalanced and exuberant immune responses termed as cytokine release" exact="syndrome" post="or cytokine storm, which triggers lung impairment and reduces"/>
 <result pre="generation of a cytokine storm. This cytokine storm results in" exact="acute" post="respiratory distress syndrome, multiple organ failure, and even death"/>
 <result pre="of a cytokine storm. This cytokine storm results in acute" exact="respiratory" post="distress syndrome, multiple organ failure, and even death (Chen,"/>
 <result pre="decrease cytokine storm might be a feasible option to reduce" exact="pulmonary" post="inflammation and mortality. Since only antiviral candidates may not"/>
 <result pre="enough to combat such cytokine storm or complications in the" exact="respiratory" post="tract, identifying effective targets for immune therapeutics along with"/>
 <result pre="has been reported to be protective against cytokine storm and" exact="neurotoxicity" post="in mouse models. Furthermore, Lenzilumab, an antiâ€�GMâ€�CSF monoclonal antibody,"/>
 <result pre="for SARS (NSPS), 2004). Recent epidemiological studies showed that SARSâ€�CoVâ€�2" exact="infection" post="in children is less frequent and lethal compared to"/>
 <result pre="Arabinoxylan treatment resulted in the upregulation of NK cells against" exact="neuroblastoma" post="in vitro and in vivo studies (PÃ©rezâ€�MartÃ­nez et al.,"/>
 <result pre="these relationships need to be elucidated in SARSâ€�CoVâ€�2 to understand" exact="disease" post="prognosis and also to enhance autophagocytosis as a possible"/>
 <result pre="COVIDâ€�19, including drugs that have already proven effective for other" exact="viral" post="diseases such as human immunodeficiency virus (HIV) and malaria."/>
 <result pre="already proven effective for other viral diseases such as human" exact="immunodeficiency" post="virus (HIV) and malaria. Drug repurposing could be a"/>
 <result pre="its worth, and different strategies might work effectively at different" exact="infection" post="stages and risk groups. The big challenge will be"/>
 <result pre="take caution to avoid mistakes that occurred during the West" exact="African" post="Ebola epidemic, in which haphazard experiments flourished and randomized"/>
 <result pre="quick and collective information regarding potential drugs. 4.1 Drugs targeting" exact="viral" post="entry As virus entry is a crucial step for"/>
 <result pre="list of repurposed drugs/chemicals that have been reported to block" exact="viral" post="entry via different mechanisms (Table 1). Monotherapy or combined"/>
 <result pre="et al. (2020) showed that Camostat mesylate interferes with TMPRSS2â€�mediated" exact="viral" post="entry, thus reduces the severity of the COVIDâ€�19 disease."/>
 <result pre="the spike protein, which may lead to the inhibition of" exact="viral" post="entry. Recently, Tian et al. (2020) identified a monoclonal"/>
 <result pre="candidate against SARSâ€�CoVâ€�2 infection. Despite the role of ACE2 in" exact="viral" post="entry, targeting interruption of ACE2 may not be the"/>
 <result pre="carried out to discover potential entry inhibitors that block that" exact="viral" post="entry without disturbing the maintenance of the blood pressure."/>
 <result pre="summarized in Tables 1 and 2. TABLE 1 Therapeutics targeting" exact="viral" post="entry Target Specific effect/target molecule Intervention(s) Status of SARSâ€�CoVâ€�2"/>
 <result pre="2, Phase 3 Lucio Manenti, Azienda Ospedalieroâ€�Universitaria di Parma, Montreal" exact="Heart" post="Institute, DACIMA Software NCT04322565, NCT04322682 Lysosome â€ 1 Bromhexine"/>
 <result pre="Early Phase 1, Phase 2, Phase 3 National Institute of" exact="Respiratory" post="Diseases, Mexico, Sanofi; Columbia University; National Institute of Respiratory"/>
 <result pre="of Respiratory Diseases, Mexico, Sanofi; Columbia University; National Institute of" exact="Respiratory" post="Diseases, Mexico, Sanofi; University of Minnesota; Rambam Health Care"/>
 <result pre="Medical University, Second Affiliated Hospital of Wenzhou Medical University, Wenzhou" exact="Central" post="Hospital NCT04273581 Spike glycoprotein Spike glycoprotein â€ 1 Nâ€�acetylcysteine"/>
 <result pre="Tongji Hospital NCT04279197 Spike glycoprotein Nitric oxide Phase 2 Massachusetts" exact="General" post="Hospital, Xijing Hospital, Fondazione IRCCS Ca' Granda, Ospedale Maggiore"/>
 <result pre="Antiâ€� SARSâ€�CoVâ€�2 plasma Phase 2, Phase 3 Sidney Kimmel Comprehensive" exact="Cancer" post="Center at Johns Hopkins; Mayo Clinic; Foundation IRCCS San"/>
 <result pre="effect/target molecule(s) Intervention(s) Status of SARSâ€�CoVâ€�2 trial Sponsor/collaborators NCT number" exact="Combined" post="intervention 3CLpro, interferon receptor (IFNAR) â€ 1 Lopinavir/ritonavir â€"/>
 <result pre="Endosomal acidification â€ 1 Azithromycin â€ 2 Hydroxychloroquine Phase 4" exact="Chronic" post="Obstructive Pulmonary Disease Trial Network, Denmark NCT04322396 ACE2 and"/>
 <result pre="acidification â€ 1 Azithromycin â€ 2 Hydroxychloroquine Phase 4 Chronic" exact="Obstructive" post="Pulmonary Disease Trial Network, Denmark NCT04322396 ACE2 and spike"/>
 <result pre="â€ 1 Azithromycin â€ 2 Hydroxychloroquine Phase 4 Chronic Obstructive" exact="Pulmonary" post="Disease Trial Network, Denmark NCT04322396 ACE2 and spike binding"/>
 <result pre="1 Azithromycin â€ 2 Hydroxychloroquine Phase 4 Chronic Obstructive Pulmonary" exact="Disease" post="Trial Network, Denmark NCT04322396 ACE2 and spike binding complex,"/>
 <result pre="Hospital Israelita Albert Einstein, EMS, Hospital do Coracao, Hospital Sirioâ€�Libanes," exact="Brazilian" post="Research In Intensive Care Network; Hospital do Coracao, Hospital"/>
 <result pre="Network; Hospital do Coracao, Hospital Israelita Albert Einstein, Hospital Sirioâ€�Libanes," exact="Brazilian" post="Research In Intensive Care Network, EMS NCT04321278, NCT04322123 Endosomal"/>
 <result pre="of Medicine and Biotechnology, Chinese Academy of Medical Sciences, Huangshi" exact="Central" post="Hospital, Shenyang Pharmaceutical University, First Affiliated Hospital of Chongqing"/>
 <result pre="of Wuhan University, The Sixth People's Hospital of Shenyang, Nanyang" exact="Central" post="Hospital NCT04286503 Spike glycoprotein, 3CLpro â€ 1 Abidol hydrochloride"/>
 <result pre="antiviral drug design. An effective antiviral agent might halt the" exact="viral" post="progression in the infected cell without being allergic or"/>
 <result pre="noninfected cells (Zhu, Meng, Wang, &amp;amp; Wang, 2015). 4.2.1 Targeting" exact="viral" post="RNA release We have already discussed above the role"/>
 <result pre="be an option for blocking this target. CQ effectively blocks" exact="viral" post="progression by raising endosomal pH needed for membrane fusion"/>
 <result pre="pH needed for membrane fusion between the host cell and" exact="viral" post="candidates and releasing RNA from endosomes (Savarino, Boelaert, Cassone,"/>
 <result pre="represent promising drug targets fora wide range of diseases, including" exact="viral" post="diseases. A few protease blockers are currently under Phase"/>
 <result pre="Interferon alfa (IFNâ€�Î±) resulted in the survival of MERSâ€�patients through" exact="viral" post="clearance (Kim, Won, Kee, Jung, &amp;amp; Jang, 2016). Some"/>
 <result pre="54â€�yearâ€�old patient administered with lopinavir/ritonavir showed a significant reduction of" exact="viral" post="loads with no or little coronavirus titers (Lim et"/>
 <result pre="associated with time to clinical improvement, mortality at 28â€‰days, detectable" exact="viral" post="RNA, and gastrointestinal adverse events compared with the standardâ€�care"/>
 <result pre="a drug as a therapeutic candidate. TABLE 3 Therapeutics intervening" exact="viral" post="replication process Target Specific effect/target molecule Intervention(s) Status of"/>
 <result pre="Capital Medical University; Gilead Sciences; National Institute of Allergy and" exact="Infectious" post="Diseases (NIAID) NCT04323761, NCT04302766, NCT04315948, NCT04252664, NCT04257656, NCT04292899, NCT04292730,"/>
 <result pre="Medical University; Gilead Sciences; National Institute of Allergy and Infectious" exact="Diseases" post="(NIAID) NCT04323761, NCT04302766, NCT04315948, NCT04252664, NCT04257656, NCT04292899, NCT04292730, NCT04280705"/>
 <result pre="(BCX4430) Phase 1 BioCryst Pharmaceuticals, National Institute of Allergy and" exact="Infectious" post="Diseases (NIAID) NCT03891420 RdRp Triazavirin Phase 3 Health Commission"/>
 <result pre="Phase 1 BioCryst Pharmaceuticals, National Institute of Allergy and Infectious" exact="Diseases" post="(NIAID) NCT03891420 RdRp Triazavirin Phase 3 Health Commission of"/>
 <result pre="4.2.3 Replication blocker RdRp is a vital enzyme of the" exact="viral" post="replication machinery; hence, RdRp blockers could be effective antiviral"/>
 <result pre="into an active ribofuranosyl triphosphate derivative that selectively inhibits the" exact="viral" post="RdRp polymerase activity (Velkov et al., 2014). Favipiravir was"/>
 <result pre="2014). Favipiravir was shown to inhibit the replication of the" exact="respiratory" post="syncytial virus and also been proven effective against influenza"/>
 <result pre="Recently, a prospective, randomized, controlled, openâ€�label multicenter trial (ChiCTR2000030254) involving" exact="adult" post="COVIDâ€�19 patients treated with Favipiravir versus Arbidol showed that"/>
 <result pre="the two arms. The Favipiravir arm showed significant improvement in" exact="chest" post="imaging, associated with faster viral clearance with lower adverse"/>
 <result pre="arm showed significant improvement in chest imaging, associated with faster" exact="viral" post="clearance with lower adverse events compared with the control"/>
 <result pre="improvement in chest imaging, associated with faster viral clearance with" exact="lower" post="adverse events compared with the control arm (Cai et"/>
 <result pre="(Foster City, CA) against the Ebola virus, incorporates into nascent" exact="viral" post="RNA chains resulting in the premature termination of RNA"/>
 <result pre="3 randomized, doubleâ€�blind, placeboâ€�controlled, multicenter study of Remdesivir in hospitalized" exact="adult" post="patients with severe COVIDâ€�19 is completed (NCT04257656). The primary"/>
 <result pre="hospitalized adult patients with severe COVIDâ€�19 is completed (NCT04257656). The" exact="primary" post="endpoint of the trial concluded that patients with COVIDâ€�19"/>
 <result pre="compared to placebo in reducing the time to recovery with" exact="lower" post="respiratory tract infection (Beigel et al., 2020). Recently, the"/>
 <result pre="to placebo in reducing the time to recovery with lower" exact="respiratory" post="tract infection (Beigel et al., 2020). Recently, the FDA"/>
 <result pre="in reducing the time to recovery with lower respiratory tract" exact="infection" post="(Beigel et al., 2020). Recently, the FDA approved the"/>
 <result pre="could interfere in the guanosine triphosphate formation, hinders capping of" exact="viral" post="mRNA, and thus inhibits viral RNAâ€�dependent RNA polymerase activity"/>
 <result pre="triphosphate formation, hinders capping of viral mRNA, and thus inhibits" exact="viral" post="RNAâ€�dependent RNA polymerase activity (Khalili, Zhu, Mak, Yan, &amp;amp;"/>
 <result pre="and RNA viruses such as paramyxovirus, Influenza A and B," exact="Hepatitis" post="C, respiratory syncytial virus, parainfluenza, and HIV (Elfiky, 2020;"/>
 <result pre="viruses such as paramyxovirus, Influenza A and B, Hepatitis C," exact="respiratory" post="syncytial virus, parainfluenza, and HIV (Elfiky, 2020; Khalili et"/>
 <result pre="which might be a therapeutic tool for reducing SARSâ€�CoVâ€�2 induced" exact="pulmonary" post="inflammation. Moreover, antiâ€�inflammatory drugs or corticosteroids might also effectively"/>
 <result pre="against FcR could be effective for an urgent remedy against" exact="pulmonary" post="inflammation associated with severe lung injury as it can"/>
 <result pre="activation. These approaches may also be applied with corticosteroids or" exact="systemic" post="antiâ€�inflammatory drugs (Shang, Zhao, Hu, Du, &amp;amp; Cao, 2020),"/>
 <result pre="needs further clinical trials to study the effectiveness against SARSâ€�CoVâ€�2" exact="infection" post="(Russell, Millar, &amp;amp; Baillie, 2020). Another potential option for"/>
 <result pre="the potential role of Siltuximab in treating patients with SARSâ€�CoVâ€�2" exact="infection" post="(Gritti et al., 2020). Furthermore, an observational caseâ€&quot;control study"/>
 <result pre="an observational caseâ€&quot;control study with 50 COVIDâ€�19 patients with serious" exact="respiratory" post="complications is ongoing in Italy to determine the effectivity"/>
 <result pre="as reduction of fever, Câ€�reactive proteins and quick relief of" exact="respiratory" post="symptoms. A clinical trial is undergoing to test whether"/>
 <result pre="Status of SARSâ€�CoVâ€�2 trial Sponsor/collaborators NCT number Immune system Immunomodulatory" exact="Mesenchymal" post="stem cell (MSC) Phase 1, Phase 2 Beijing 302"/>
 <result pre="Inc. NCT04317040 Interferon gamma (IFNy) Emapalumab Phase 2, Phase 3" exact="Swedish" post="Orphan Biovitrum NCT04324021 Interferon receptor (IFNAR) â€ 1 Recombinant"/>
 <result pre="interferon ÃŽ Â±â€‰1ÃŽ2 Early Phase 1 Tongji Hospital NCT04293887 Interleukinâ€�1" exact="type 1" post="receptor Anakinra Phase 2, Phase 3 Swedish Orphan Biovitrum"/>
 <result pre="NCT04293887 Interleukinâ€�1 type 1 receptor Anakinra Phase 2, Phase 3" exact="Swedish" post="Orphan Biovitrum NCT04324021 Interleukinâ€�1 type 1 receptor â€ 1"/>
 <result pre="Anakinra Phase 2, Phase 3 Swedish Orphan Biovitrum NCT04324021 Interleukinâ€�1" exact="type 1" post="receptor â€ 1 RoActemra iv â€ 2 RoActemra sc"/>
 <result pre="Marius Henriksen, Lars Erik Kristensen, Frederiksberg University Hospital NCT04322773 Interleukinâ€�1" exact="type 1" post="receptor Sarilumab Phase 2, Phase 3 Assistance Publique â€�"/>
 <result pre="Marche, Azienda Ospedaliera Ospedali Riuniti Marche Nord; Hoffmannâ€�La Roche, National" exact="Cancer" post="Institute, Naples; Tongji Hospital, Hubei Xinhua Hospital, Wuhan No.1"/>
 <result pre="COVIDâ€�19. A vaccine can be either prophylactic, which prevents future" exact="infection" post="or therapeutic, which is used to treat diseases such"/>
 <result pre="or therapeutic, which is used to treat diseases such as" exact="cancer" post="or infectious diseases (Frazer, 2014; Guo et al., 2013)."/>
 <result pre="which is used to treat diseases such as cancer or" exact="infectious diseases" post="(Frazer, 2014; Guo et al., 2013). The whole pathogen"/>
 <result pre="al., 2003; Kim et al., 2014). However, there is no" exact="benign" post="and operational vaccine available against SARSâ€�CoV until now. Development"/>
 <result pre="a foundation and a template for developing vaccines against MERSâ€�CoV" exact="infection" post="(Jiang, Lu, &amp;amp; Du, 2013). However, only one MERSâ€�CoV"/>
 <result pre="trial (Yong, Ong, Yeap, Ho, &amp;amp; Tan, 2019). Several more" exact="viral" post="vectoredâ€�MERSâ€�CoV vaccines are in progress (Yong et al., 2019)"/>
 <result pre="(1) inactivated or weakened whole virus, (2) nucleic acid, (3)" exact="viral" post="vector, and (4) protein subunit or virusâ€�like particles (Figure"/>
 <result pre="an immune response in the body, which might prevent subsequent" exact="infection" post="of SARSâ€�CoVâ€�2 (Lane, 2020). The Phase 1 trial initiated"/>
 <result pre="vaccine, a synthetic strand of mRNA, which translates the prefusionâ€�stabilized" exact="viral" post="spike protein. The mRNAs, after intramuscular injection, are predicted"/>
 <result pre="trial yet, and no vaccines are available to prevent SARSâ€�CoVâ€�2" exact="infection" post="(Amanat &amp;amp; Krammer, 2020; Chen, Zhang, et al., 2020b)."/>
 <result pre="(b) Nucleic acid vaccine: Contains the genetic material only; (c)" exact="Viral" post="vector vaccine: A genetically modified virus that can generate"/>
 <result pre="Covidâ€�19/aAPC vaccine Phase 1 Shenzhen Genoâ€�Immune Medical Institute NCT04299724 Nonreplicating" exact="viral" post="vector AZD1222 (ChAdOx1 nCoVâ€�19) Phase 1/2/3 Consortium of the"/>
 <result pre="of Biotechnology and so on NCT04313127, NCT04341389, NCT04398147, ChiCTR2000031781, ChiCTR2000030906" exact="Protein" post="subunit NVXâ€�CoV2373 (SARSâ€�CoVâ€�2 rS) Phase 1 Novavax NCT04368988 SCBâ€�2019"/>
 <result pre="plasma or sera) of people who have recuperated from SARSâ€�CoVâ€�2" exact="infection" post="are used to enhance the immunity of newly infected"/>
 <result pre="sera or plasma were used effectively in the past during" exact="mumps" post="and measles epidemics (Casadevall &amp;amp; Pirofski, 2020). This approach"/>
 <result pre="plasma were used effectively in the past during mumps and" exact="measles" post="epidemics (Casadevall &amp;amp; Pirofski, 2020). This approach has already"/>
 <result pre="in China, where five SARSâ€�CoVâ€�2 infected, severely ill patients with" exact="acute" post="respiratory distress syndrome were treated with convalescent plasma transfusion"/>
 <result pre="China, where five SARSâ€�CoVâ€�2 infected, severely ill patients with acute" exact="respiratory" post="distress syndrome were treated with convalescent plasma transfusion from"/>
 <result pre="five SARSâ€�CoVâ€�2 infected, severely ill patients with acute respiratory distress" exact="syndrome" post="were treated with convalescent plasma transfusion from five different"/>
 <result pre="of the treated patients (Shen et al., 2020). However, the" exact="limited" post="number of participants in this study precludes a definitive"/>
 <result pre="is monoclonal antibody therapy. Bevacizumab, a humanized monoclonal antibody, blocks" exact="vascular" post="endothelial growth factor (VEGF) to halt the angiogenesis in"/>
 <result pre="vascular endothelial growth factor (VEGF) to halt the angiogenesis in" exact="cancer" post="patients (Ellis, 2006). A Phase 3 randomized, doubleâ€�blind, placeboâ€�controlled,"/>
 <result pre="3 randomized, doubleâ€�blind, placeboâ€�controlled, multicenter study of Remdesivir in hospitalized" exact="adult" post="patients with severe COVIDâ€�19 has been completed (NCT04257656). A"/>
 <result pre="reduce the VEGF level and reduce the severity of the" exact="disease" post="(Wang, Cai, et al., 2004). 7 CONCLUSION AND FUTURE"/>
 <result pre="on the potential drug targets of therapeutic promise against SARSâ€�CoVâ€�2" exact="infection" post="and highlighted the application of the drug repurposing approach."/>
 <result pre="current clinical trials mostly based on repurposing the therapeutic agents" exact="formerly" post="designed for other indications that have been rapidly started"/>
 <result pre="(2014). Evaluation of SSYA10â€�001 as a replication inhibitor of severe" exact="acute" post="respiratory syndrome, mouse hepatitis, and Middle East respiratory syndrome"/>
 <result pre="Evaluation of SSYA10â€�001 as a replication inhibitor of severe acute" exact="respiratory" post="syndrome, mouse hepatitis, and Middle East respiratory syndrome coronaviruses."/>
 <result pre="of severe acute respiratory syndrome, mouse hepatitis, and Middle East" exact="respiratory" post="syndrome coronaviruses. Antimicrobial Agents and Chemotherapy, 58(8), 4894â€&quot;4898. 10.1128/aac.02994-1424841268"/>
 <result pre="severe acute respiratory syndrome, mouse hepatitis, and Middle East respiratory" exact="syndrome" post="coronaviruses. Antimicrobial Agents and Chemotherapy, 58(8), 4894â€&quot;4898. 10.1128/aac.02994-1424841268 Amanat,"/>
 <result pre="&amp;amp; Baker, S. C. (2005). The papainâ€�like protease of severe" exact="acute" post="respiratory syndrome coronavirus has deubiquitinating activity. Journal of Virology,"/>
 <result pre="Baker, S. C. (2005). The papainâ€�like protease of severe acute" exact="respiratory" post="syndrome coronavirus has deubiquitinating activity. Journal of Virology, 79(24),"/>
 <result pre="S. C. (2005). The papainâ€�like protease of severe acute respiratory" exact="syndrome" post="coronavirus has deubiquitinating activity. Journal of Virology, 79(24), 15189â€&quot;15198."/>
 <result pre="J. (2006). Important role for the transmembrane domain of severe" exact="acute" post="respiratory syndrome coronavirus spike protein during entry. Journal of"/>
 <result pre="(2006). Important role for the transmembrane domain of severe acute" exact="respiratory" post="syndrome coronavirus spike protein during entry. Journal of Virology,"/>
 <result pre="Important role for the transmembrane domain of severe acute respiratory" exact="syndrome" post="coronavirus spike protein during entry. Journal of Virology, 80(3),"/>
 <result pre="Brown, N. A. (2009). Progress towards improving antiviral therapy for" exact="hepatitis C" post="with hepatitis C virus polymerase inhibitors. Part I: Nucleoside"/>
 <result pre="(2009). Progress towards improving antiviral therapy for hepatitis C with" exact="hepatitis C" post="virus polymerase inhibitors. Part I: Nucleoside analogues. Expert Opinion"/>
 <result pre="(2015). Treatment with Lopinavir/ritonavir or interferonâ€�Î²1b improves outcome of MERSâ€�CoV" exact="infection" post="in a nonhuman primate model of common marmoset. The"/>
 <result pre="a nonhuman primate model of common marmoset. The Journal of" exact="Infectious" post="Diseases, 212(12), 1904â€&quot;1913. 10.1093/infdis/jiv39226198719 Channappanavar, R., Fehr, A. R.,"/>
 <result pre="Zhao, J., Meyerholz, D. K., &amp;amp; Perlman, S. (2016). Dysregulated" exact="type I" post="interferon and inflammatory monocyteâ€�macrophage responses cause lethal pneumonia in"/>
 <result pre="Dysregulated type I interferon and inflammatory monocyteâ€�macrophage responses cause lethal" exact="pneumonia" post="in SARSâ€�CoVâ€�infected mice. Cell Host &amp;amp; Microbe, 19(2), 181â€&quot;193."/>
 <result pre="the research of cytokine storm mechanism induced by Corona virus" exact="disease" post="2019 and the corresponding immunotherapies. Zhonghua Shao Shang Za"/>
 <result pre="R., &amp;amp; Subbarao, K. (2010). Cellular immune responses to severe" exact="acute" post="respiratory syndrome coronavirus (SARSâ€�CoV) infection in senescent BALB/c mice:"/>
 <result pre="&amp;amp; Subbarao, K. (2010). Cellular immune responses to severe acute" exact="respiratory" post="syndrome coronavirus (SARSâ€�CoV) infection in senescent BALB/c mice: CD4+"/>
 <result pre="Subbarao, K. (2010). Cellular immune responses to severe acute respiratory" exact="syndrome" post="coronavirus (SARSâ€�CoV) infection in senescent BALB/c mice: CD4+ T"/>
 <result pre="Cellular immune responses to severe acute respiratory syndrome coronavirus (SARSâ€�CoV)" exact="infection" post="in senescent BALB/c mice: CD4+ T cells are important"/>
 <result pre="Convalescent plasma as a potential therapy for COVIDâ€�19. The Lancet" exact="Infectious" post="Diseases, 20(4), 398â€&quot;400. 10.1016/s1473-3099(20)30141-932113510 Chen, W.â€�H., Strych, U., Hotez,"/>
 <result pre="Will children reveal their secret? The Coronavirus Dilemma. The European" exact="Respiratory" post="Journal. 10.1183/13993003.00749-2020 Croston, G. E. (2017). The utility of"/>
 <result pre="FDAâ€�approved compound library identifies four smallâ€�molecule inhibitors of Middle East" exact="respiratory" post="syndrome coronavirus replication in cell culture. Antimicrobial Agents and"/>
 <result pre="compound library identifies four smallâ€�molecule inhibitors of Middle East respiratory" exact="syndrome" post="coronavirus replication in cell culture. Antimicrobial Agents and Chemotherapy,"/>
 <result pre="innate immunity by the papainâ€�like protease domain of the severe" exact="acute" post="respiratory syndrome coronavirus. The Journal of Biological Chemistry, 282(44),"/>
 <result pre="immunity by the papainâ€�like protease domain of the severe acute" exact="respiratory" post="syndrome coronavirus. The Journal of Biological Chemistry, 282(44), 32208â€&quot;32221."/>
 <result pre="by the papainâ€�like protease domain of the severe acute respiratory" exact="syndrome" post="coronavirus. The Journal of Biological Chemistry, 282(44), 32208â€&quot;32221. 10.1074/jbc.M70487020017761676"/>
 <result pre="and functional exhaustion of T cells in patients with coronavirus" exact="disease" post="2019 (COVIDâ€�19). medRxiv 2020.2002.2018.20024364. doi:10.1101/2020.02.18.20024364%J Dong, X., Dong, X.,"/>
 <result pre="response occurs via activation of the NFâ€�kappaB pathway in human" exact="monocyte" post="macrophages in vitro. Virus Research, 142(1â€&quot;2), 19â€&quot;27. 10.1016/j.virusres.2009.01.00519185596 Du,"/>
 <result pre="of action of bevacizumab as a component of therapy for" exact="metastatic" post="colorectal cancer. Seminars in Oncology, 33(5 Suppl 10), S1â€&quot;S7."/>
 <result pre="action of bevacizumab as a component of therapy for metastatic" exact="colorectal cancer." post="Seminars in Oncology, 33(5 Suppl 10), S1â€&quot;S7. 10.1053/j.seminoncol.2006.08.002 Fan,"/>
 <result pre="Lai, L. (2004). Biosynthesis, purification, and substrate specificity of severe" exact="acute" post="respiratory syndrome coronavirus 3Câ€�like proteinase. The Journal of Biological"/>
 <result pre="L. (2004). Biosynthesis, purification, and substrate specificity of severe acute" exact="respiratory" post="syndrome coronavirus 3Câ€�like proteinase. The Journal of Biological Chemistry,"/>
 <result pre="(2004). Biosynthesis, purification, and substrate specificity of severe acute respiratory" exact="syndrome" post="coronavirus 3Câ€�like proteinase. The Journal of Biological Chemistry, 279(3),"/>
 <result pre="R. E., Mesecar, A. D., &amp;amp; Baric, R. S. (2009)." exact="Severe" post="acute respiratory syndrome coronavirus papainâ€�like protease ubiquitinâ€�like domain and"/>
 <result pre="E., Mesecar, A. D., &amp;amp; Baric, R. S. (2009). Severe" exact="acute" post="respiratory syndrome coronavirus papainâ€�like protease ubiquitinâ€�like domain and catalytic"/>
 <result pre="Mesecar, A. D., &amp;amp; Baric, R. S. (2009). Severe acute" exact="respiratory" post="syndrome coronavirus papainâ€�like protease ubiquitinâ€�like domain and catalytic domain"/>
 <result pre="A. D., &amp;amp; Baric, R. S. (2009). Severe acute respiratory" exact="syndrome" post="coronavirus papainâ€�like protease ubiquitinâ€�like domain and catalytic domain regulate"/>
 <result pre="Nakamura, T. (2017). Favipiravir (Tâ€�705), a broad spectrum inhibitor of" exact="viral" post="RNA polymerase. Proceedings of the Japan Academy. Series B,"/>
 <result pre="&amp;amp; PÃ¶hlmann, S. (2011). Evidence that TMPRSS2 activates the severe" exact="acute" post="respiratory syndrome coronavirus spike protein for membrane fusion and"/>
 <result pre="PÃ¶hlmann, S. (2011). Evidence that TMPRSS2 activates the severe acute" exact="respiratory" post="syndrome coronavirus spike protein for membrane fusion and reduces"/>
 <result pre="S. (2011). Evidence that TMPRSS2 activates the severe acute respiratory" exact="syndrome" post="coronavirus spike protein for membrane fusion and reduces viral"/>
 <result pre="respiratory syndrome coronavirus spike protein for membrane fusion and reduces" exact="viral" post="control by the humoral immune response. Journal of Virology,"/>
 <result pre="J., Drosten, C., Gulyaeva, A. A., &amp;amp; Ziebuhr, J. (2020)." exact="Severe" post="acute respiratory syndromeâ€�related coronavirus: The species and its virusesâ€&quot;A"/>
 <result pre="Drosten, C., Gulyaeva, A. A., &amp;amp; Ziebuhr, J. (2020). Severe" exact="acute" post="respiratory syndromeâ€�related coronavirus: The species and its virusesâ€&quot;A statement"/>
 <result pre="C., Gulyaeva, A. A., &amp;amp; Ziebuhr, J. (2020). Severe acute" exact="respiratory" post="syndromeâ€�related coronavirus: The species and its virusesâ€&quot;A statement of"/>
 <result pre="a directâ€�acting antiviral that inhibits RNAâ€�dependent RNA polymerase from severe" exact="acute" post="respiratory syndrome coronavirus 2 with high potency. Journal of"/>
 <result pre="directâ€�acting antiviral that inhibits RNAâ€�dependent RNA polymerase from severe acute" exact="respiratory" post="syndrome coronavirus 2 with high potency. Journal of Biological"/>
 <result pre="antiviral that inhibits RNAâ€�dependent RNA polymerase from severe acute respiratory" exact="syndrome" post="coronavirus 2 with high potency. Journal of Biological Chemistry."/>
 <result pre="Ambrosino, D. M. (2005). Development and characterization of a severe" exact="acute" post="respiratory syndromeâ€�associated coronavirusâ€�neutralizing human monoclonal antibody that provides effective"/>
 <result pre="D. M. (2005). Development and characterization of a severe acute" exact="respiratory" post="syndromeâ€�associated coronavirusâ€�neutralizing human monoclonal antibody that provides effective immunoprophylaxis"/>
 <result pre="antibody that provides effective immunoprophylaxis in mice. The Journal of" exact="Infectious" post="Diseases, 191(4), 507â€&quot;514. 10.1086/42724215655773 Gritti, G., Raimondi, F., Ripamonti,"/>
 <result pre="Rambaldi, A. (2020). Use of siltuximab in patients with COVIDâ€�19" exact="pneumonia" post="requiring ventilatory support. medRxiv 2020.2004.2001.20048561. doi:10.1101/2020.04.01.20048561%J. Guo, C., Manjili,"/>
 <result pre="Sarkar, D., Fisher, P. B., &amp;amp; Wang, X.â€�Y. (2013). Therapeutic" exact="cancer" post="vaccines: Past, present, and future. Advances in Cancer Research,"/>
 <result pre="(2013). Therapeutic cancer vaccines: Past, present, and future. Advances in" exact="Cancer" post="Research, 119, 421â€&quot;475. 10.1016/B978-0-12-407190-2.00007-123870514 Guo, J., Huang, Z., Lin,"/>
 <result pre="J., Huang, Z., Lin, L., &amp;amp; Lv, J. (2020). Coronavirus" exact="disease" post="2019 (COVIDâ€�19) and cardiovascular disease: A viewpoint on the"/>
 <result pre="L., &amp;amp; Lv, J. (2020). Coronavirus disease 2019 (COVIDâ€�19) and" exact="cardiovascular" post="disease: A viewpoint on the potential influence of angiotensinâ€�converting"/>
 <result pre="enzyme inhibitors/angiotensin receptor blockers on onset and severity of severe" exact="acute" post="respiratory syndrome coronavirus 2 infection. Journal of the American"/>
 <result pre="inhibitors/angiotensin receptor blockers on onset and severity of severe acute" exact="respiratory" post="syndrome coronavirus 2 infection. Journal of the American Heart"/>
 <result pre="receptor blockers on onset and severity of severe acute respiratory" exact="syndrome" post="coronavirus 2 infection. Journal of the American Heart Association,"/>
 <result pre="severe acute respiratory syndrome coronavirus 2 infection. Journal of the" exact="American" post="Heart Association, 9(7), e01621910.1161/jaha.120.01621932233755 Hamming, I., Timens, W., Bulthuis,"/>
 <result pre="acute respiratory syndrome coronavirus 2 infection. Journal of the American" exact="Heart" post="Association, 9(7), e01621910.1161/jaha.120.01621932233755 Hamming, I., Timens, W., Bulthuis, M."/>
 <result pre="A., Paul, S., Khan, k., &amp;amp; Barua, P. (2020). Zika" exact="viral" post="proteome analysis reveals an epitope cluster within NS3 helicase"/>
 <result pre="Seraj, Z. I. (2018). Multiâ€�Epitope Cluster Ep85B within the Mycobacterial" exact="Protein" post="Ag85B Elicits Cellâ€�Mediated and Humoral Responses in Mice. Turkish"/>
 <result pre="Zhang, B., Wang, H., Wu, Y., &amp;amp; Rao, Z. (2020)." exact="Structural" post="basis for the inhibition of SARSâ€�CoVâ€�2 main protease by"/>
 <result pre="inhibition of SARSâ€�CoVâ€�2 main protease by antineoplastic drug carmofur. Nature" exact="Structural" post="&amp;amp; Molecular Biology, 27, 529â€&quot;532. 10.1038/s41594-020-0440-6 Kadam, R. U.,"/>
 <result pre="529â€&quot;532. 10.1038/s41594-020-0440-6 Kadam, R. U., &amp;amp; Wilson, I. A. (2017)." exact="Structural" post="basis of influenza virus fusion inhibition by the antiviral"/>
 <result pre="glycoprotein by airway proteases enhances virus entry into human bronchial" exact="epithelial" post="cells in vitro. PLoS One, 4(11), e787010.1371/journal.pone.000787019924243 Kandeel, M.,"/>
 <result pre="CoVs to SARSâ€�CoVâ€�2: Moving toward more biased codon usage in" exact="viral" post="structural and nonstructural genes. Journal of Medical Virology, 92(6),"/>
 <result pre="pilot clinical trial of recombinant human angiotensinâ€�converting enzyme 2 in" exact="acute" post="respiratory distress syndrome. Critical Care, 21(1), 23410.1186/s13054-017-1823-x28877748 Khan, M."/>
 <result pre="clinical trial of recombinant human angiotensinâ€�converting enzyme 2 in acute" exact="respiratory" post="distress syndrome. Critical Care, 21(1), 23410.1186/s13054-017-1823-x28877748 Khan, M. K.,"/>
 <result pre="&amp;amp; Gambotto, A. (2014). Immunogenicity of an adenoviralâ€�based Middle East" exact="respiratory" post="syndrome coronavirus vaccine in BALB/c mice. Vaccine, 32(45), 5975â€&quot;5982."/>
 <result pre="Gambotto, A. (2014). Immunogenicity of an adenoviralâ€�based Middle East respiratory" exact="syndrome" post="coronavirus vaccine in BALB/c mice. Vaccine, 32(45), 5975â€&quot;5982. 10.1016/j.vaccine.2014.08.05825192975"/>
 <result pre="Combination therapy with lopinavir/ritonavir, ribavirin and interferonâ€�Î± for Middle East" exact="respiratory" post="syndrome. Antiviral Therapy, 21(5), 455â€&quot;459. 10.3851/imp300226492219 Kirchdoerfer, R. N.,"/>
 <result pre="Development by selfâ€�digestion: Molecular mechanisms and biological functions of autophagy." exact="Developmental" post="Cell, 6(4), 463â€&quot;477. 10.1016/s1534-5807(04)00099-115068787 Li, F. (2015). Receptor recognition"/>
 <result pre="&amp;amp; Harrison, S. C. (2006). Conformational states of the severe" exact="acute" post="respiratory syndrome coronavirus spike protein ectodomain. Journal of Virology,"/>
 <result pre="Harrison, S. C. (2006). Conformational states of the severe acute" exact="respiratory" post="syndrome coronavirus spike protein ectodomain. Journal of Virology, 80(14),"/>
 <result pre="S. C. (2006). Conformational states of the severe acute respiratory" exact="syndrome" post="coronavirus spike protein ectodomain. Journal of Virology, 80(14), 6794â€&quot;6800."/>
 <result pre="M. J., Luo, S., &amp;amp; Farzan, M. (2005). Receptor and" exact="viral" post="determinants of SARSâ€�coronavirus adaptation to human ACE2. The EMBO"/>
 <result pre="EMBO Journal, 24(8), 1634â€&quot;1643. 10.1038/sj.emboj.760064015791205 Liesegang, T. J. (2009). Varicella" exact="zoster" post="virus vaccines: effective, but concerns linger. Canadian Journal of"/>
 <result pre="of the index patient who caused tertiary transmission of COVIDâ€�19" exact="infection" post="in Korea: The application of Lopinavir/ritonavir for the treatment"/>
 <result pre="The application of Lopinavir/ritonavir for the treatment of COVIDâ€�19 infected" exact="pneumonia" post="monitored by quantitative RTâ€�PCR. Journal of Korean Medical Science,"/>
 <result pre="&amp;amp; MÃ©nard, R. (2005). The papainâ€�like protease from the severe" exact="acute" post="respiratory syndrome coronavirus is a deubiquitinating enzyme. Journal of"/>
 <result pre="MÃ©nard, R. (2005). The papainâ€�like protease from the severe acute" exact="respiratory" post="syndrome coronavirus is a deubiquitinating enzyme. Journal of Virology,"/>
 <result pre="R. (2005). The papainâ€�like protease from the severe acute respiratory" exact="syndrome" post="coronavirus is a deubiquitinating enzyme. Journal of Virology, 79(24),"/>
 <result pre="protease TMPRSS2 activates a proteolytic cascade involving components of the" exact="tumor" post="microenvironment and promotes prostate cancer metastasis. Cancer Discovery, 4(11),"/>
 <result pre="proteolytic cascade involving components of the tumor microenvironment and promotes" exact="prostate cancer" post="metastasis. Cancer Discovery, 4(11), 1310â€&quot;1325. 10.1158/2159-8290.Cd-13-101025122198 Lung, J., Lin,"/>
 <result pre="cascade involving components of the tumor microenvironment and promotes prostate" exact="cancer" post="metastasis. Cancer Discovery, 4(11), 1310â€&quot;1325. 10.1158/2159-8290.Cd-13-101025122198 Lung, J., Lin,"/>
 <result pre="components of the tumor microenvironment and promotes prostate cancer metastasis." exact="Cancer" post="Discovery, 4(11), 1310â€&quot;1325. 10.1158/2159-8290.Cd-13-101025122198 Lung, J., Lin, Y. S.,"/>
 <result pre="Stahl, M., &amp;amp; Penninger, J. M. (2020). Inhibition of SARSâ€�CoVâ€�2" exact="infections" post="in engineered human tissues using clinicalâ€�grade soluble human ACE2."/>
 <result pre="the past: Possible urgent prevention and treatment options for severe" exact="acute" post="respiratory infections caused by 2019â€�nCoV. ChemBioChem, 21(5), 730â€&quot;738. 10.1002/cbic.20200004732022370"/>
 <result pre="past: Possible urgent prevention and treatment options for severe acute" exact="respiratory" post="infections caused by 2019â€�nCoV. ChemBioChem, 21(5), 730â€&quot;738. 10.1002/cbic.20200004732022370 collab:"/>
 <result pre="Possible urgent prevention and treatment options for severe acute respiratory" exact="infections" post="caused by 2019â€�nCoV. ChemBioChem, 21(5), 730â€&quot;738. 10.1002/cbic.20200004732022370 collab: National"/>
 <result pre="involvement of natural killer cells in the pathogenesis of severe" exact="acute" post="respiratory syndrome. (2004). American Journal of Clinical Pathology, 121(4),"/>
 <result pre="of natural killer cells in the pathogenesis of severe acute" exact="respiratory" post="syndrome. (2004). American Journal of Clinical Pathology, 121(4), 507â€&quot;511."/>
 <result pre="cells in the pathogenesis of severe acute respiratory syndrome. (2004)." exact="American" post="Journal of Clinical Pathology, 121(4), 507â€&quot;511. 10.1309/wpk7-y2xk-nf4c-bf3r15080302 Nikolichâ€�Zugich, J.,"/>
 <result pre="Arabinoxylan rice bran (MGNâ€�3/biobran) enhances natural killer cellâ€�mediated cytotoxicity against" exact="neuroblastoma" post="in vitro and in vivo. Cytotherapy, 17(5), 601â€&quot;612. 10.1016/j.jcyt.2014.11.00125541298"/>
 <result pre="Y., &amp;amp; Jung, S. H. (2016). An overview of severe" exact="acute" post="respiratory syndromeâ€�coronavirus (SARSâ€�CoV) 3CL protease inhibitors: Peptidomimetics and small"/>
 <result pre="&amp;amp; Jung, S. H. (2016). An overview of severe acute" exact="respiratory" post="syndromeâ€�coronavirus (SARSâ€�CoV) 3CL protease inhibitors: Peptidomimetics and small molecule"/>
 <result pre="S. C., Stevens, R. C., &amp;amp; Mesecar, A. D. (2006)." exact="Severe" post="acute respiratory syndrome coronavirus papainâ€�like protease: Structure of a"/>
 <result pre="C., Stevens, R. C., &amp;amp; Mesecar, A. D. (2006). Severe" exact="acute" post="respiratory syndrome coronavirus papainâ€�like protease: Structure of a viral"/>
 <result pre="Stevens, R. C., &amp;amp; Mesecar, A. D. (2006). Severe acute" exact="respiratory" post="syndrome coronavirus papainâ€�like protease: Structure of a viral deubiquitinating"/>
 <result pre="R. C., &amp;amp; Mesecar, A. D. (2006). Severe acute respiratory" exact="syndrome" post="coronavirus papainâ€�like protease: Structure of a viral deubiquitinating enzyme."/>
 <result pre="Severe acute respiratory syndrome coronavirus papainâ€�like protease: Structure of a" exact="viral" post="deubiquitinating enzyme. Proceedings of the National Academy of Sciences"/>
 <result pre="C., &amp;amp; Ambrosino, D. M. (2006). Therapy with a severe" exact="acute" post="respiratory syndromeâ€�associated coronavirusâ€�neutralizing human monoclonal antibody reduces disease severity"/>
 <result pre="&amp;amp; Ambrosino, D. M. (2006). Therapy with a severe acute" exact="respiratory" post="syndromeâ€�associated coronavirusâ€�neutralizing human monoclonal antibody reduces disease severity and"/>
 <result pre="a severe acute respiratory syndromeâ€�associated coronavirusâ€�neutralizing human monoclonal antibody reduces" exact="disease" post="severity and viral burden in golden Syrian hamsters. The"/>
 <result pre="respiratory syndromeâ€�associated coronavirusâ€�neutralizing human monoclonal antibody reduces disease severity and" exact="viral" post="burden in golden Syrian hamsters. The Journal of Infectious"/>
 <result pre="and viral burden in golden Syrian hamsters. The Journal of" exact="Infectious" post="Diseases, 193(5), 685â€&quot;692. 10.1086/50014316453264 Russell, C. D., Millar, J."/>
 <result pre="C. (2016). Review of siltuximab in the treatment of multicentric" exact="Castleman's disease." post="Therapeutic Advances in Hematology, 7(6), 360â€&quot;366. 10.1177/204062071665374527904739 Savarino, A.,"/>
 <result pre="Majori, G., &amp;amp; Cauda, R. (2003). Effects of chloroquine on" exact="viral" post="infections: An old drug against today's diseases?The Lancet Infectious"/>
 <result pre="on viral infections: An old drug against today's diseases?The Lancet" exact="Infectious" post="Diseases, 3(11), 722â€&quot;727. 10.1016/s1473-3099(03)00806-514592603 Seybert, A., Posthuma, C. C.,"/>
 <result pre="(2015). Immunoinformatics aided prediction of cytotoxic T cell epitope of" exact="respiratory" post="syncytial virus. Bioresearch Communications (BRC), 1(2), 99â€&quot;104. Shang, L.,"/>
 <result pre="An orally bioavailable broadâ€�spectrum antiviral inhibits SARSâ€�CoVâ€�2 in human airway" exact="epithelial" post="cell cultures and multiple coronaviruses in mice. Science Translational"/>
 <result pre="ill patients with COVIDâ€�19 with convalescent plasma. Journal of the" exact="American" post="Medical Association, 323, 158210.1001/jama.2020.4783 Shulla, A., Healdâ€�Sargent, T., Subramanya,"/>
 <result pre="(2011). A Transmembrane serine protease is linked to the severe" exact="acute" post="respiratory syndrome coronavirus receptor and activates virus entry. Journal"/>
 <result pre="A Transmembrane serine protease is linked to the severe acute" exact="respiratory" post="syndrome coronavirus receptor and activates virus entry. Journal of"/>
 <result pre="Transmembrane serine protease is linked to the severe acute respiratory" exact="syndrome" post="coronavirus receptor and activates virus entry. Journal of Virology,"/>
 <result pre="Piefer, A. J., &amp;amp; Bates, P. (2004). Characterization of severe" exact="acute" post="respiratory syndromeâ€�associated coronavirus (SARSâ€�CoV) spike glycoproteinâ€�mediated viral entry. Proceedings"/>
 <result pre="A. J., &amp;amp; Bates, P. (2004). Characterization of severe acute" exact="respiratory" post="syndromeâ€�associated coronavirus (SARSâ€�CoV) spike glycoproteinâ€�mediated viral entry. Proceedings of"/>
 <result pre="Characterization of severe acute respiratory syndromeâ€�associated coronavirus (SARSâ€�CoV) spike glycoproteinâ€�mediated" exact="viral" post="entry. Proceedings of the National Academy of Sciences of"/>
 <result pre="The M, E, and N structural proteins of the severe" exact="acute" post="respiratory syndrome coronavirus are required for efficient assembly, trafficking,"/>
 <result pre="M, E, and N structural proteins of the severe acute" exact="respiratory" post="syndrome coronavirus are required for efficient assembly, trafficking, and"/>
 <result pre="E, and N structural proteins of the severe acute respiratory" exact="syndrome" post="coronavirus are required for efficient assembly, trafficking, and release"/>
 <result pre="&amp;amp; Kenderian, S. S. (2019). GMâ€�CSF inhibition reduces cytokine release" exact="syndrome" post="and neuroinflammation but enhances CARâ€�T cell function in xenografts."/>
 <result pre="S. S. (2019). GMâ€�CSF inhibition reduces cytokine release syndrome and" exact="neuroinflammation" post="but enhances CARâ€�T cell function in xenografts. Blood, 133(7),"/>
 <result pre="novel coronavirus: Implication for development of RBD protein as a" exact="viral" post="attachment inhibitor and vaccine. Cellular &amp;amp; Molecular Immunology, 17,"/>
 <result pre="B., &amp;amp; Stanton, L. W. (2004). Inhibition of SARS coronavirus" exact="infection" post="in vitro with clinically approved antiviral drugs. Emerging Infectious"/>
 <result pre="coronavirus infection in vitro with clinically approved antiviral drugs. Emerging" exact="Infectious" post="Diseases, 10(4), 581â€&quot;586. 10.3201/eid1004.03045815200845 Tanner, J. A., Watt, R."/>
 <result pre="Peiris, J. S., &amp;amp; Huang, J. D. (2003). The severe" exact="acute" post="respiratory syndrome (SARS) coronavirus NTPase/helicase belongs to a distinct"/>
 <result pre="J. S., &amp;amp; Huang, J. D. (2003). The severe acute" exact="respiratory" post="syndrome (SARS) coronavirus NTPase/helicase belongs to a distinct class"/>
 <result pre="S., &amp;amp; Huang, J. D. (2003). The severe acute respiratory" exact="syndrome" post="(SARS) coronavirus NTPase/helicase belongs to a distinct class of"/>
 <result pre="NTPase/helicase belongs to a distinct class of 5â€² to 3â€²" exact="viral" post="helicases. The Journal of Biological Chemistry, 278(41), 39578â€&quot;39582. 10.1074/jbc.C30032820012917423"/>
 <result pre="Wang, C., Li, Z., Koerhuis, D., &amp;amp; Veesler, D. (2019)." exact="Structural" post="basis for human coronavirus attachment to sialic acid receptors."/>
 <result pre="basis for human coronavirus attachment to sialic acid receptors. Nature" exact="Structural" post="&amp;amp; Molecular Biology, 26(6), 481â€&quot;489. 10.1038/s41594-019-0233-y Tripp, R. A.,"/>
 <result pre="neutralizing and antibodies reactive to S, N, M and E" exact="viral" post="proteins. Journal of Virological Methods, 128(1â€&quot;2), 21â€&quot;28. 10.1016/j.jviromet.2005.03.02115885812 Velkov,"/>
 <result pre="(2004). Efficacy and safety of arbidol in treatment of naturally" exact="acquired" post="influenza. Zhongguo Yi Xue Ke Xue Yuan Xue Bao,"/>
 <result pre="optimized dosing Design of Hydroxychloroquine for the treatment of severe" exact="acute" post="respiratory syndrome coronavirus 2 (SARSâ€�CoVâ€�2). Clinical Infectious Diseases. 10.1093/cid/ciaa237"/>
 <result pre="dosing Design of Hydroxychloroquine for the treatment of severe acute" exact="respiratory" post="syndrome coronavirus 2 (SARSâ€�CoVâ€�2). Clinical Infectious Diseases. 10.1093/cid/ciaa237 Yong,"/>
 <result pre="Design of Hydroxychloroquine for the treatment of severe acute respiratory" exact="syndrome" post="coronavirus 2 (SARSâ€�CoVâ€�2). Clinical Infectious Diseases. 10.1093/cid/ciaa237 Yong, C."/>
 <result pre="treatment of severe acute respiratory syndrome coronavirus 2 (SARSâ€�CoVâ€�2). Clinical" exact="Infectious" post="Diseases. 10.1093/cid/ciaa237 Yong, C. Y., Ong, H. K., Yeap,"/>
 <result pre="(2019). Recent advances in the vaccine development against Middle East" exact="respiratory" post="syndromeâ€�coronavirus. Frontiers in Microbiology, 10, 1781â€&quot;1781. 10.3389/fmicb.2019.0178131428074 Zhang, H.,"/>
 <result pre="pathogenic GMâ€�CSF T cells and inflammatory CD14 monocytes in severe" exact="pulmonary" post="syndrome patients of a new coronavirus. bioRxiv 2020.2002.2012.945576. doi:10.1101/2020.02.12.945576%J"/>
 <result pre="GMâ€�CSF T cells and inflammatory CD14 monocytes in severe pulmonary" exact="syndrome" post="patients of a new coronavirus. bioRxiv 2020.2002.2012.945576. doi:10.1101/2020.02.12.945576%J Zhu,"/>
</results>
